Drug Profile


Alternative Names: Anti-HER2-monoclonal-antibody-Green-Cross; MGAH-22

Latest Information Update: 08 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Raven biotechnologies
  • Developer Green Cross; MacroGenics; Merck Sharp & Dohme
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Breast cancer
  • Phase I/II Gastric cancer
  • Phase I Bladder cancer; Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 27 Apr 2017 MacroGenics initiates an expanded access for Breast cancer (Metastatic disease) in USA (NCT03133988)
  • 14 Apr 2017 MacroGenics completes a phase II trial in Breast cancer (Second-line therapy or greater, Late-stage disease) in USA (NCT01828021)
  • 01 Jan 2016 Phase-I/II clinical trials in Gastric cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT02689284)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top